ATYR 5-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Core Viewpoint - A securities class action lawsuit has been filed against aTyr Pharma, Inc. following an 83% stock collapse after the failure of its flagship drug trial, Efzofitimod, to meet its primary endpoint [1] Summary by Relevant Sections Legal Allegations - The lawsuit alleges that aTyr and its executives provided materially false and misleading information regarding the efficacy of Efzofitimod, leading to inflated stock prices [1] - The core issue revolves around whether the company accurately represented its clinical trial data and design [1] Clinical Trial Performance - The primary endpoint of the Phase 3 EFZO-FIT study was not met, specifically regarding the change from baseline in mean daily oral corticosteroid (OCS) dose [1] - Allegations include the concealment of adverse facts about the drug's ability to allow patients to taper off steroids completely, which is a key measure of efficacy [1] Market Impact - Following the announcement of the trial results, aTyr's stock price plummeted from $6.03 to $1.02, representing an 83.2% loss [1] - The lawsuit seeks to determine if investors are entitled to damages due to the alleged wrongful acts and omissions by the defendants [1] Next Steps for Investors - Hagens Berman is advising investors who purchased aTyr shares during the class period (November 7, 2024, through September 12, 2025) and suffered losses to submit their claims [1] - The deadline for investors to move for appointment as lead plaintiff is December 8, 2025 [1]